Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acorafloxacin

Drug Profile

Acorafloxacin

Alternative Names: Avarofloxacin; JNJ-32729463; JNJ-32729463-AAA; JNJ-Q2

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen
  • Developer Furiex Pharmaceuticals; Janssen
  • Class Antibacterials; Carboxylic acids; Fluorocarbons; Fluoroquinolones; Piperidines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Community-acquired pneumonia; Skin and soft tissue infections

Most Recent Events

  • 07 May 2014 Avarofloxacin is available for licensing as of 07 May 2014. http://www.furiex.com
  • 25 Feb 2013 Avarofloxacin receives Fast Track designation for Skin and soft tissue infections and Community-acquired pneumonia in USA
  • 25 Feb 2013 Avarofloxacin receives Qualified Infectious Disease Product (QIDP) designation from the US FDA for Skin and soft tissue infections and Community-acquired pneumonia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top